Christine A. Nash
Independent DirectorMs. Christine A. Nash, M.B.A., serves as an Independent Director at Rallybio Corporation since April 2022. She serves as Senior Advisor at NaviMed Capital Advisors, LLC. She had been Director of Rallybio, LLC since 2022. Since April 2018, she has been a principal at Chatiemac Consulting, LLC. She was the Chief Commercial Officer and Senior Vice President of Hyperion Therapeutics, Inc., since May 2012. Ms. Nash served as the Vice President of Corporate Business Development and Strategic Marketing at Hyperion Therapeutics, Inc. from August 2008 to May 2012. At CoTherix Inc., Ms. Nash served as Director of Marketing where she led all marketing and product support aspects of the launch of its initial product, Ventavis® (iloprost) Inhalation Solution, an orphan drug. She was employed at Genesoft Pharmaceuticals where she led preparation for its inaugural product launch and was a Member of the senior team responsible for the sale of its to Genome Therapeutics. Her previous experience includes business development and product planning and management roles with Oncology Therapeutics Network, Eli Lilly and Company and Imana, Inc. Ms. Nash holds BA with Honors in Public Policy and MBA both from Stanford University.
Positions
- Company NameRallybio CorporationStock CodeRLYBPositionIndependent Director
